The Challenge
In preparation to optimise the chances of successful Global launches of selected pipeline assets, a major pharmaceutical company, wished to conduct an initial value assessment in potential new indication to understanding the value to key stakeholders.
Solution
We conducted a comprehensive initial value assessment to identify, prioritise, and propose methods for validating and quantifying key value elements. Our approach included a detailed review of existing evidence, categorisation of value blocks using targeted literature reviews (TLR), and the application of early quantification approaches considering core value components (survival, QoL, and costs).
We engaged both internal and external stakeholders to validate priorities and ensure alignment. This process provided a clear map of evidence strengths and gaps, informed early market access and health economic strategies, and expanded the definition of value by validating key value blocks with patients, clinicians, and payers.
Impact
Our support helped the client to successfully obtain a comprehensive overview and categorisation of existing evidence and data gaps to inform early market access planning, early health economic modelling and value proposition work.
